


Now in its fifth year, the National Pharmaceutical Council's annual survey of health care stakeholders continues to shed light on the environment for comparative effectiveness research (CER) and health care decision-making.


THE STAKEHOLDERS WE SURVEYED...



SAID CER IS IMPORTANT...




BUT ITS IMPACT ON DECISION-MAKING IS STILL 3-5 YEARS DOWN THE ROAD.




For key roles, stakeholders were asked to choose among the Agency for Healthcare Research and Quality (AHRQ), the National Institutes of Health (NIH), the Food and Drug Administration (FDA), the Patient-Centered Outcomes Research Institute (PCORI), academia, private health plans and the biopharmaceutical industry. N=122 for Stakeholders Surveyed. N=115 for Importance of CER. N=114 for Impact of CER in the Past Year and 1 Year; N=115 for the Next 3 Years and Next 5 Years. N=117 for remaining figures.

STAKEHOLDERS ALSO TOLD US WHICH ORGANIZATIONS ARE PLAYING KEY ROLES IN THE CER EFFORT.


KEY ROLES IN SETTING CER PRIORITIES




KEY PLAYERS IN SETTING RESEARCH STANDARDS




KEY ROLES IN FUNDING, MONITORING RESEARCH



KEY GROUPS IN CONDUCTING CER



KEY PLAYERS IN DISSEMINATING CER



View the complete survey results and related materials and download our booklet, *2015 Comparative Effectiveness Research and the Environment for Health Care Decision-Making* at www.npcnow.org/cersurvey15.